Humacyte (HUMA) Non-cash Items (2020 - 2026)

Humacyte (HUMA) reported Non-cash Items of $8.5 million for Q1 2026, down 47.59% quarter-over-quarter from $16.2 million in Q4 2024.

Humacyte (HUMA) Non-cash Items (2020 - 2026) Analysis & Trends

Humacyte (HUMA) has 4 years of Non-cash Items data on file, last reported at $8.5 million in Q1 2026.

Non-cash Items for Q1 2026 came in at $8.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $8.5 million (changed N/A YoY), and the FY2025 annual result was $7.7 million, down 52.77% from the prior year.
Non-cash Items retreated to $8.5 million in Q1 2026 per HUMA's latest filing, from $16.2 million in the prior quarter.
Over five years, Non-cash Items peaked at $16.2 million in Q4 2024 and troughed at $8.5 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Humacyte	267.09 Mn	218.55 Mn	-1.54 Mn

Download Data